Navigation Links
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
Date:2/12/2008

h flows support our reinvestment in future growth as we seek to enhance operational performance and provide added value to our core customers."

2008 Performance Outlook

For the full-year 2008, Genoptix expects revenues of approximately $90 million, resulting from expanded sales efforts and additional increases in case volumes.

The company also expects net income for 2008 of between $15 and $17 million (assuming an annual tax rate of 5% after utilizing our net operating loss carryforwards), which includes the impact of an estimated $6 million in non-cash stock-based compensation, an increase resulting primarily from expenses associated with the initiation of the Company's equity incentive programs. GAAP earnings per diluted share are expected to be in the range of $0.85 to $0.95 for the full year 2008.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company is projecting capital expenditures of between $4 million and $6 million for the full-year 2008.

Conference Call Information

A conference call will take place on Tuesday, February 12, 2008, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO Tina Nova Bennett, Ph.D., and other members of senior management. To access the live conference call via phone, dial 888-713-4214 in the U.S. or Canada and 617-213-4866 for international callers. The participant code for the call is 56532675. A replay of the call will be available through Friday, February 22, 2008. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 77232785.

The conference call will also be webcast live on the Internet and is accessible through the investor relations section of the Genoptix website at http://www.genoptix.com, or by accessing the external website, '/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
2. Genoptix, Inc. Announces Pricing for Initial Public Offering
3. MIB Life Index Reports North American Life Insurance Activity Up 1.4% in December
4. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
5. Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results
6. Mesa Labs Reports Higher Quarterly Sales and Earnings
7. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
8. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
9. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Neurobiological Technologies Reports Second Quarter Financial Results
11. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... MONROVIA, Calif., July 24 /PRNewswire-FirstC... leading developer, manufacturer and marketer of,m...nced that the Centers,for Medicare and Medicaid Se...heric cataract lenses as New Technology Intraocula...amer(R) Aspheric Single Piece foldable,intraocular...
(Date:7/24/2008)... Ground-breaking Technology Debuts in the Trance... Shoe, BOTHELL, Wash., July 24 /PRNewswi...Sports, Inc. today announced that BioMoGo, the wor... to consumers in the new Trance(TM),8 premium supp... times,faster than conventional athletic shoe mids...
(Date:7/24/2008)... NEW YORK, July 24 /PRNewswire/ -- MS -- Toda...nt things. For those who care for their,bodies, by...ations for,anti-aging, it is possible to feel and ...http://www.newscom.com/cgi-bin/prnh/20080724/NYFNS...uthor, and frequent guest on,Oprah Winfrey,s progr...
(Date:7/24/2008)... SCHAUMBURG, Ill., July 24 /PRNewswire/ -- A ...America,s most chronic problems -- obesity -- in,p... weight problem. About one third of us are,obese, ...ets -- they really,do look like us -- mirror us wi...esity, a public/private partnership that includes,...
Breaking Medicine News(10 mins):Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 2Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 3Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 4Health News:Brooks(R) Sports Launches BioMoGo Biodegradable Shoe 2Health News:Brooks(R) Sports Launches BioMoGo Biodegradable Shoe 3Health News:Live to 100 ... And Feel Great 2Health News:PetFit Challenge Helps Keep Pets - and Pet Owners - Healthy 2
...ndia has declined over the century from 972 in 190... to 933 in 2001. In contrast, the child sex rati...rls per thousand boys against 945 recorded in 1991...tio is concerned, it is 1.01 male (s)/females as i...
...ntessentially Indian puff, has become a victim of ...outhern districts of Tamil Nadu going on strike. ...wrapped in leaf, from Tirunelveli, Tuticorin and K...this weekend to protest the union health ministry ...
...Democratic Front (LDF) government, set to mark its...at it is to blame for the deaths of 38 newborns in...fection in the labour room of the Sree Avittam Tir...the last two months. A court has charged Health M...
...is of concern as it is a reflection of the prevale...s and the extent of transmission of TB infection ...orted under the programme are of paediatric age gr...ntage of paediatric cases reported at national lev...
Other Medicine News:Health News:Bidi Workers Protest Against Using Skull and Crossbones Sign on Packets 2
(Date:7/23/2008)...py to Treat the Disease -, WAYNE, N.J. and EMERYV...yer HealthCare Pharmaceuticals and Onyx Pharmaceut...e New England Journal of Medicine published,result... (sorafenib),tablets decreased the absolute risk o...e hepatocellular carcinoma (HCC), or liver cancer,...
(Date:7/23/2008).../ -- The following was,released by the U.S. Depart...r Smith, and Members of the Committee.,Thank you f...eared before this Committee almost six months ago,...ented and dedicated professionals,at the Justice D...me to,appreciate that much more deeply their servi...
(Date:7/23/2008)...ode BioPharmaceutics, Inc.,an emerging biopharmac...results demonstrating the utility of their lead dr...hronic blood disorder paroxysmal nocturnal,hemoglo...ted at the XXII,International Complement Workshop ...nly treatment currently available for PNH patients...
(Date:7/22/2008)...irstCall/ -- Following a,thorough review that conc...uticals Limited (ASX: PGL; Nasdaq: PGLA) today ann...study in liver cancer. Progen confirmed,its strate... compounds and,the company will actively seek to a...ugh Merger & Acquisition activity., The strategic...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen 28R 29 Technology at Lower Doses 1558 1Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen 28R 29 Technology at Lower Doses 1558 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen 28R 29 Technology at Lower Doses 1558 3Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 1Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 2Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 3Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 4Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 5National Parkinson Foundation Announces Its New President and CEO 14689 1National Parkinson Foundation Announces Its New President and CEO 14689 2National Parkinson Foundation Announces Its New President and CEO 14689 3Michigan State Medical Society Will Present How VEBA is Shifting Michigans Health Care Gears 14686 1
Our Tri-Flo® suction catheter design was created to be less traumatic to your patients while still providing high suctioning efficiency. Our infant and pediatric catheters (5/6, 8 or 10 Fr) featu
Tracheal Suction Latex Rubber Catheters - Funnel End
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip.
KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning.
Medicine Products: